Anti-SLAM / CD150 Antibody [SLAM.4] (PE) (A281742)

Anti-SLAM / CD150 Antibody [SLAM.4] (PE)

Mouse monoclonal [SLAM.4] antibody to SLAM / CD150 (PE).

This antibody recognises CD150 also known as signaling lymphocyte activation molecule (SLAM), is a member of the immunoglobulin superfamily. CD150 is expressed in dendritic cells, Natural Killer (NK) cells, B and T cells. CD150 is a membrane phosphoglycoprotein which contains 2 extracellular domains corresponding to a variable and constant region, a general feature of the Ig superfamily. CD150 also has a cytoplasmic domain which contains 3 unique tyrosine motifs with a conserved TxYxxV sequence. This tyrosine motif is the binding domain for SLAM-associated protein (SAP) which form a complex together (Sayos et al 1998, Poy et al. 1999). This complex plays a role in the regulation of Natural killer (NK) and T cell development. Mutations to SAP in humans results in X-linked lymphoproliferative disease which is a fatal immunological disorder. Activation of CD150 co-activates T- or B-lymphocytes responses and plays a role in bidirectional T-B cell stimulation. It can also regulate NK and T cell development, B cell regulation and antibody production/isotype switching (Veillette 2006). CD150 is also the receptor that the measles virus recognises. The SLAM.4 clone has been used in flow cytometry to analyze the cell distribution of CD150 on leucocytes and lymphocytes as well as to distinguish between subsets of CD4+ and CD8+ T lymphocytes.

Flow Cytometry: Neat, Use 10µl of the undiluted reagent to label 1x10⁶ cells in 100µl

Human

Human CD150-transfected 300.19 cells.

Mouse

Monoclonal

SLAM.4

IgG1

PE

Excitation: 565nm, Emission: 578nm

Lot Specific

>95% (by SDS-PAGE).

Liquid

Supplied in Phosphate Buffered Saline with 0.2% BSA and <0.1% Sodium Azide.

Store undiluted at 4°C. Do not freeze! This product is photosensitive and should be protected from light.

Mouse anti Human CD150 antibody, clone SLAM.4 recognizes CD150 also known as signaling lymphocyte activation molecule (SLAM), is a member of the immunoglobulin superfamily. CD150 is expressed in dendritic cells, Natural Killer (NK) cells, B and T cells (Bhattocharjee and Yadava 2018). CD150 is a membrane phosphoglycoprotein which contains 2 extracellular domains corresponding to a variable and constant region, a general feature of the Ig superfamily (Cocks et al. 1995). CD150 also has a cytoplasmic domain which contains 3 unique tyrosine motifs with a conserved TxYxxV sequence. This tyrosine motif is the binding domain for SLAM-associated protein (SAP) which form a complex together (Sayos et al 1998, Poy et al. 1999). This complex plays a role in the regulation of Natural killer (NK) and T cell development. Mutations to SAP in humans results in X-linked lymphoproliferative disease which is a fatal immunological disorder (Coffey et al. 1998). Activation of CD150 co-activates T- or B-lymphocytes responses and plays a role in bidirectional T-B cell stimulation (Carballido et al. 1997). It can also regulate NK and T cell development, B cell regulation and antibody production/isotype switching (Veillette 2006). CD150 is also the receptor that the measles virus recognizes (Tatsuo et al. 2000). The SLAM.4 clone has been used in flow cytometry to analyze the cell distribution of CD150 on leucocytes and lymphocytes as well as to distinguish between subsets of CD4+ and CD8+ T lymphocytes (Romero et al. 2001).

4933415F16, AA177906, CD 150, CD150, CD150 antigen, CDw150, Estm51, Ipo 3, IPO-3, Ipo3, MGC151472, MGC151476, OTTHUMP00000025670, OTTHUMP00000060252, RGD1560634, Signaling lymphocytic activation molecule, Signaling lymphocytic activation molecule family member 1, Signaling lymphocytic activation molecule family member 1, isoform CRA_a, Signaling lymphocytic activation molecule family member 1, isoform CRA_b, Signaling lymphocytic activation molecule precursor, Slaf1, SLAF1_HUMAN, SLAM family, member 1, Slamf 1, SLAMF1, SLAMF1 protein

This product is for research use only. It is not intended for diagnostic or therapeutic use.